RVP Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -18.58% compared to Retractable Technologies's net margin of 5.12%. Retractable Technologies's return on equity of -16.83% beat InfuSystems Holdings's return on equity of 2.8%.

Retractable Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 72.05%. Given that InfuSystems Holdings has higher upside potential than Retractable Technologies, analysts believe InfuSystems Holdings is more attractive than Retractable Technologies.

Retractable Technologies has a beta of 1.979, which suggesting that the stock is 97.877% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

Retractable Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Retractable Technologies pays -3.32% of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Retractable Technologies quarterly revenues are $10.3M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Retractable Technologies's net income of -$1.9M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Retractable Technologies's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 129.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Retractable Technologies is 0.50x versus 1.33x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -18.58% compared to Retractable Technologies's net margin of --. Retractable Technologies's return on equity of -16.83% beat Plus Therapeutics's return on equity of --.

Retractable Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1358.33%. Given that Plus Therapeutics has higher upside potential than Retractable Technologies, analysts believe Plus Therapeutics is more attractive than Retractable Technologies.

Retractable Technologies has a beta of 1.979, which suggesting that the stock is 97.877% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.519%.

Retractable Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Retractable Technologies pays -3.32% of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Retractable Technologies quarterly revenues are $10.3M, which are larger than Plus Therapeutics quarterly revenues of --. Retractable Technologies's net income of -$1.9M is higher than Plus Therapeutics's net income of -$2.9M. Notably, Retractable Technologies's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Retractable Technologies is 0.50x versus 1.18x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -18.58% compared to Retractable Technologies's net margin of -4291.67%. Retractable Technologies's return on equity of -16.83% beat Catheter Precision's return on equity of -65.84%.

Retractable Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Retractable Technologies, analysts believe Catheter Precision is more attractive than Retractable Technologies.

Retractable Technologies has a beta of 1.979, which suggesting that the stock is 97.877% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Retractable Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Retractable Technologies pays -3.32% of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Retractable Technologies quarterly revenues are $10.3M, which are larger than Catheter Precision quarterly revenues of $96K. Retractable Technologies's net income of -$1.9M is higher than Catheter Precision's net income of -$4.1M. Notably, Retractable Technologies's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Retractable Technologies is 0.50x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -18.58% compared to Retractable Technologies's net margin of -17.98%. Retractable Technologies's return on equity of -16.83% beat Xtant Medical Holdings's return on equity of -35.98%.

Retractable Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Retractable Technologies, analysts believe Xtant Medical Holdings is more attractive than Retractable Technologies.

Retractable Technologies has a beta of 1.979, which suggesting that the stock is 97.877% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Retractable Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Retractable Technologies pays -3.32% of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Retractable Technologies quarterly revenues are $10.3M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Retractable Technologies's net income of -$1.9M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Retractable Technologies's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Retractable Technologies is 0.50x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.